SUNRISE, Fla., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, ...
The MarketWatch News Department was not involved in the creation of this content. SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical ...
NEW YORK--(BUSINESS WIRE)--CI&T (NYSE: CINT), a global digital specialist, announces today, as a complement to the market announcement of August 16, 2022, the completion of the acquisition of ...
SUNRISE, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., a U.S. based, clinical-stage, revenue-generating biopharmaceutical company focused on developing inhaled therapeutics for ...
• TRB-ONC1 granted U.S. Orphan Drug Designation by the FDA for the treatment of glioblastoma (GBM) SUNRISE, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated, clinical-stage ...
Transpire Bio has tapped Recipharm to support the development of its inhaled respiratory disease drug candidates. The agreement positions Transpire to tap into Recipharm’s experience of developing and ...
SUNRISE, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, ...
WESTON, Fla., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, ...
SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results